Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.93 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.93 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.60 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.60 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KDM5C | P41229 | 3/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.41 |
| ▸ | KDM6B | O15054 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alpha-Ketoglutaric Acid SCHEMBL28583724 | 1.00 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL3776640 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL30208560 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL30029036 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL932116 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL17127347 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL7400 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL29783374 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL1242830 | 0.93 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL20877597 | 0.93 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3980001-B1 | SUSTAINED-RELEASE COMPOSITIONS OF ALPHA-KETOGLUTARATE | PONCE DE LEON HEALTH DESIGNATED ACTIVITY COMPANY (IE) | 2025-08-27 | — | — | EP | claimed |
| WO-2025096390-A1 | AUTO-EXPRESSION BROTH AND USES THEREOF | UNIVERSITY OF MONTANA (US) | 2025-05-08 | — | — | WO | claimed |
| CN-112955139-B | Process for preparing alpha-ketoglutarate calcium | 庞塞迪利昂健康特定活动公司 | 2025-04-18 | — | — | CN | claimed |
| EP-3398594-B1 | COMPOSITIONS FOR IMPROVEMENT OF BRAIN FUNCTION | GRESPO AB (SE) | 2024-07-10 | — | — | EP | claimed |
| US-11802103-B2 | Process of making calcium alpha-ketoglutarate | PONCE DE LEON HEALTH DESIGNATED ACTIVITY COMPANY (IE) | 2023-10-31 | — | — | US | claimed |
| CN-115974679-A | Preparation method of alpha-ketoglutarate calcium salt | 绍兴市精益生物化工有限公司 | 2023-04-18 | — | — | CN | claimed |
| US-20230085573-A1 | Compositions and Methods for Treating Aging-Related Disorders | AGELESS SCIENCES INC (US) | 2023-03-16 | — | — | US | claimed |
| EP-4096439-A1 | COMPOSITIONS AND METHODS FOR TREATING AGING-RELATED DISORDERS | Ageless Sciences, Inc. (US) | 2022-12-07 | — | — | EP | claimed |
| CN-112941116-B | Method for preparing alpha-ketoglutarate calcium by enzyme method | 上海朴颐化学科技有限公司 | 2022-12-02 | — | — | CN | claimed |
| US-11504351-B2 | Methods for restoring stem cell pools and reducing epigenetic age | DISCHLER LOUIS (US) | 2022-11-22 | — | — | US | claimed |
| WO-2020252005-A1 | METHODS AND COMPOSITIONS FOR ALTERING SENESCENCE ASSOCIATED SECRETORY PHENOTYPE | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2020-12-17 | — | — | WO | claimed |
| WO-2020068705-A1 | PROCESS OF MAKING CALCIUM ALPHA-KETOGLUTARATE | PONCE DE LEON HEALTH DESIGNATED ACTIVITY COMPANY (IE) | 2020-04-02 | — | — | WO | claimed |
| EP-2897604-B1 | COMPOSITIONS FOR IMPROVEMENT OF BRAIN FUNCTION | GRESPO AB (SE) | 2018-07-04 | — | — | EP | claimed |
| EP-2173336-B1 | Alpha-ketoglutaric acid for use in the treatment of hypertension or pulmonary hypertension | PROTISTA BIOTECHNOLOGY AB (SE) | 2016-03-30 | — | — | EP | claimed |
| US-20150297544-A1 | COMPOSITIONS FOR IMPROVEMENT OF BRAIN FUNCTION | GRESPO AB (SE) | 2015-10-22 | — | — | US | claimed |
| EP-2897604-A1 | COMPOSITIONS FOR IMPROVEMENT OF BRAIN FUNCTION | Grespo AB (SE) | 2015-07-29 | — | — | EP | claimed |
| WO-2014046603-A1 | COMPOSITIONS FOR IMPROVEMENT OF BRAIN FUNCTION | GRESPO AB (SE) | 2014-03-27 | — | — | WO | claimed |
| US-20110039935-A1 | USE OF PHARMACOLOGICALLY ACTIVE CHEMICAL COMPOUNDS | ENTRESS AB (SE) | 2011-02-17 | — | — | US | claimed |
| EP-2173336-A1 | NEW USE OF KNOWN PHARMACOLOGICALLY ACTIVE CHEMICAL COMPOUNDS | Entress AB (SE) | 2010-04-14 | — | — | EP | claimed |
| WO-2009005464-A1 | NEW USE OF KNOWN PHARMACOLOGICALLY ACTIVE CHEMICAL COMPOUNDS | ENTRESS AB (SE) | 2009-01-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297544-A1 | COMPOSITIONS FOR IMPROVEMENT OF BRAIN FUNCTION | PYGB, GAA, AMY2A | EGLN1 1643/4885OR51E2 4749/4885MAPK1 3153/4885 |
| US-11802103-B2 | Process of making calcium alpha-ketoglutarate | HOGA1, OGDH, GLS | EGLN1 211/4885OR51E2 4773/4885MAPK1 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.